

PARTICULARS TO APPEAR ON THE OUTER PACKAGE
CARDBOARD OR PLASTIC (PET) BOX (10 or 50 vials)

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

Nobivac Parvo-C Lyophilisate for Suspension for Injection for Dogs

2. STATEMENT OF ACTIVE SUBSTANCES

Each 1 ml dose of reconstituted vaccine contains:

Canine parvovirus (CPV), strain 154, live $\geq 10^{7.0}$ TCID₅₀

3. PACKAGE SIZE

10 x 1 dose

50 x 1 dose

4. TARGET SPECIES

Dogs.

5. INDICATIONS

6. ROUTES OF ADMINISTRATION

Subcutaneous use.

7. WITHDRAWAL PERIODS

8. EXPIRY DATE

Exp. {mm/yyyy}

Once reconstituted use within 30 minutes.

9. SPECIAL STORAGE PRECAUTIONS

Store in a refrigerator.

Do not freeze.

Protect from light.

Avoid prolonged and repetitive exposure to high ambient temperature.

10. THE WORDS “READ THE PACKAGE LEAFLET BEFORE USE”

Read the package leaflet before use.

11. THE WORDS “FOR ANIMAL TREATMENT ONLY”

For animal treatment only.

12. THE WORDS “KEEP OUT OF THE SIGHT AND REACH OF CHILDREN”

Keep out of the sight and reach of children.

13. NAME OF THE MARKETING AUTHORISATION HOLDER

Intervet International B.V.

14. MARKETING AUTHORISATION NUMBERS

Vm 06376/4105

15. BATCH NUMBER

Lot {number}

MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING
UNITS
GLASS VIAL LABEL

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

Nobivac Parvo-C



2. QUANTITATIVE PARTICULARS OF THE ACTIVE SUBSTANCES

1 dose

Live CPV $\geq 10^{7.0}$ TCID₅₀

3. BATCH NUMBER

Lot {number}

4. EXPIRY DATE

Exp. {mm/yyyy}

Once reconstituted use within 30 minutes.

PARTICULARS TO APPEAR ON THE PACKAGE LEAFLET:

PACKAGE LEAFLET

1. Name of the veterinary medicinal product

Nobivac Parvo-C Lyophilisate for Suspension for Injection for Dogs

2. Composition

Each 1 ml dose of reconstituted vaccine contains:

Active substance:

Canine parvovirus (CPV), strain 154, live $\geq 10^{7.0}$ TCID₅₀*

*Tissue culture infective dose 50%

Lyophilisate: off-white or cream-coloured pellet.

3. Target species

Dogs.

4. Indications for use

For active immunisation of dogs to prevent mortality, clinical signs and viral excretion following canine parvovirus infection.

Onset of immunity: 1 week.

Duration of immunity: 3 years.

5. Contraindications

None.

6. Special warnings

Special warnings:

Vaccinate healthy animals only.

The vaccine may not be effective in dogs incubating the disease at the time of vaccination.

A good immune response is reliant on the reaction of an immunogenic agent and a fully competent immune system.

Immunocompetence of the animal may be compromised by a variety of factors including poor health, nutritional status, genetic factors, concurrent drug therapy and stress.

The immunogenicity of the vaccine antigen will be reduced by poor storage or inappropriate administration.

The vaccine has been proved to be of benefit against virulent challenge in the presence of maternal antibody levels to CPV that are likely to be encountered under field conditions.

Experience has shown that the maternal antibody status of pups within a litter varies greatly, and reliance should not be placed on serological examination of the bitch alone.

Special precautions for safe use in the target species:

Animals that have received a corresponding anti-serum or immunosuppressive drugs should not be vaccinated until an interval of at least 4 weeks has elapsed.

Vaccinated dogs may excrete the parvovirus vaccine strain at very low levels for up to 8 days after vaccination. However, there is no evidence of any reversion to virulence of the vaccine strain and therefore no need to separate unvaccinated dogs from contact with recently vaccinated dogs.

Special precautions to be taken by the person administering the veterinary medicinal product to animals:

In case of accidental self-injection, seek medical advice immediately and show the package leaflet or the label to the physician.

Pregnancy:

Can be used during pregnancy.

Pregnant bitches should have been previously vaccinated with the CPV (strain 154) antigen included in the Nobivac vaccine range.

Interaction with other medicinal products and other forms of interaction:

Safety and efficacy data are available which demonstrate that this vaccine can be mixed and administered with the inactivated vaccines in the Nobivac range against canine leptospirosis caused by all or some of the following serovars: *L. interrogans* serogroup Canicola serovar Canicola, *L. interrogans* serogroup Icterohaemorrhagiae serovar Copenhageni, *L. interrogans* serogroup Australis serovar Bratislava, and *L. kirschneri* serogroup Grippotyphosa serovar Bananal/Liangguang.

After administration with one of the leptospirosis vaccines, a mild and transient increase in body temperature (≤ 1 °C) may occur for a few days after vaccination, with some pups showing less activity and/or a reduced appetite. A small transient swelling (≤ 4 cm), which can occasionally be firm and painful on palpation, may be observed at the site of injection. Any such swelling will either have disappeared or be clearly diminished by 14 days post-vaccination.

After mixed administration of an overdose of this vaccine and an overdose of the leptospirosis vaccines in the Nobivac range, transient local reactions such as diffuse to firm swellings from 1 to 5 cm in diameter may be observed, usually these will persist no longer than 5 weeks, however some may take a little longer to completely disappear.

Safety and efficacy data are available which demonstrate that this vaccine can be mixed and administered with the inactivated vaccine in the Nobivac range against rabies. After administration with the rabies vaccine, where this product is authorised, transient local reactions such as diffuse to firm swellings from 1 to 4 cm in diameter may be observed for up to 3 weeks after vaccination. The swellings may be painful for up to 3 days post vaccination.

Safety and efficacy data are available which demonstrate that this vaccine can be administered at the same time but not mixed with the inactivated vaccine of in Nobivac range against *Bordetella bronchiseptica*.

Product information of the relevant Nobivac vaccines should be consulted before mixed product administration.

No information is available on the safety and efficacy of this vaccine when used with any other veterinary medicinal product except the products mentioned above. A decision to use this vaccine before or after any other veterinary medicinal product therefore needs to be made on a case by case basis.

Overdose:

No clinical signs other than those mentioned in section Adverse events. In some dogs the swelling may be more painful or may be observed for a longer period.

Major incompatibilities:

Do not mix with any other veterinary medicinal product except solvent supplied for use with the veterinary medicinal product or the Nobivac dog vaccines mentioned above.

7. Adverse events

Dogs:

Common (1 to 10 animals / 100 animals treated):	Injection site swelling ^{1,2}
Very rare (<1 animal / 10,000 animals treated, including isolated reports):	Hypersensitivity reaction (e.g. lethargy, facial oedema, pruritus, vomiting or diarrhoea) ^{2,3}

¹ Diffuse, up to 5 mm in diameter, which can occasionally be hard and painful and can last for up to 3 days post injection.

² Transient, shortly after vaccination.

³ Such reaction may evolve to a more severe condition (anaphylaxis), which may be life-threatening with additional signs like dyspnoea and collapse. If such reaction occurs, appropriate treatment is recommended.

Reporting adverse events is important. It allows continuous safety monitoring of a product. If you notice any side effects, even those not already listed in this package leaflet, or you think that the medicine has not worked, please contact, in the first instance, your veterinarian. You can also report any adverse events to the marketing authorisation holder or the local representative of the marketing authorisation holder using the contact details at the end of this leaflet, or via your national reporting system at:

Website: <https://www.gov.uk/report-veterinary-medicine-problem/animal-reacts-medicine>

E-mail: adverse.events@vmd.gov.uk

8. Dosage for each species, routes and method of administration

Subcutaneous use.

Reconstitute the vaccine with 1 ml solvent or 1 ml (1 dose) of the inactivated vaccines mentioned in section Special warnings.

Maternal antibodies can negatively interfere with the efficacy of a vaccine. Strict adherence to the vaccination programme is therefore recommended.

Vaccination programme:

Primary vaccination:

A single injection should establish active immunity to disease caused by canine parvovirus infection in dogs of 10 weeks of age or older.

Where earlier protection is required a first dose may be given to puppies from 4 weeks of age, but because maternally derived passive antibodies can interfere with the response to vaccination, a final dose at 10 weeks of age or older is generally recommended.

Revaccination:

It is recommended that dogs be revaccinated against canine parvovirus every 3 years.

9. Advice on correct administration

Sterile equipment should be used for administration.

Avoid contamination of vaccine with traces of chemical sterilising agents. Do not use chemicals such as disinfectant or spirit to disinfect the skin prior to administration.

10. Withdrawal periods

Not applicable.

11. Special storage precautions

Keep out of the sight and reach of children.

Store in a refrigerator (2 °C – 8 °C).

Do not freeze.

Protect from light.

Avoid prolonged or repetitive exposure to high ambient temperatures following withdrawal from the refrigerator prior to use. In hot summer conditions vaccine potency can be severely reduced within a few hours.

Do not use this veterinary medicinal product after the expiry date which is stated on the label and outer box after 'EXP'. The expiry date refers to the last day of that month.

Shelf life after reconstitution according to directions: 30 minutes.

12. Special precautions for disposal

Medicines should not be disposed of via wastewater or household waste.

Use take-back schemes for the disposal of any unused veterinary medicinal product or waste materials derived thereof in accordance with local requirements and with any applicable national collection systems.

These measures should help to protect the environment.

13. Classification of veterinary medicinal products

Veterinary medicinal product subject to prescription.

14. Marketing authorisation numbers and pack sizes

Vm 06376/4105

Pack sizes:

Cardboard or plastic (PET) box containing 10 x 1 dose or 50 x 1 dose vials.

Not all pack sizes may be marketed.

15. PID LINK (Do not print heading)

[The following statement must be included where reference to the European Union Product Database is included on the product information. This statement is relevant to both UK(GB) and UK(NI) products:]

Find more product information by searching for the 'Product Information Database' on www.gov.uk.

16. Contact details

Marketing authorisation holder and manufacturer responsible for batch release:

Intervet International B.V.
Wim de Körverstraat 35
5831 AN Boxmeer
Netherlands

Contact details to report suspected adverse events:

UK(GB):

MSD Animal Health UK Limited
Tel.: +44 (0)1908 685685

UK(NI):

Intervet Ireland Ltd.
Tel.: +353 (0)1 2970220

Local representative:

MSD Animal Health UK Limited
Walton Manor
Walton
Milton Keynes
MK7 7AJ, United Kingdom

For any information about this veterinary medicinal product, please contact the local representative of the marketing authorisation holder.

17. Other information

POM-V

Gavin Hall
Approved: 26 February 2026